New Antifungal Analogs

Summary

 

Technology Description

 

This technology licensing opportunity provides biosynthetic methods for the production of the antidiabetic drug voglibose. Briefly, antifungal validamycin A analogs, including 1,1′-bis-valienamine, are produced using valN mutant strains of Streptomyces organisms, such as Streptomyces hygroscopicus. The 1,1′-bis-valienamine product can be easily converted to valienamine, which in turn is converted to voglibose.

 

Features & Benefits

 

  • Provides biosynthetic production of voglibose precursors for improved manufacturing.

 

Applications

 

  • Manufacturing antidiabetics.

 

Background of Invention

 

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Diabetes is a chronic, lifelong condition that often requires management with diabetes medications. It has been estimated that almost 30 million Americans, or 9.3% of the population, have diabetes, and diabetes remains the 7th leading cause of death in America. In order to combat the growing problem of diabetes and related healthcare costs, both new medications and more cost effective methods for manufacturing existing diabetes medications are needed.

 

Status

 

Issued U.S. Patent 8,101,732

 

 

 

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Methods of Producing Validamycin A Analogs and Uses Thereof US Non-provisional United States 12/560,283 8,101,732 9/15/2009 1/24/2012 10/8/2029
Tech ID:
OSU-07-67
Category(s):
Therapeutics
Agricultural
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Taifo Mahmud
Hui Xu
Jongtae Yang
Zixin Deng
Linquan Bai
Keywords:
Agriculture
Biomedical
Drug
drugs
Medical Science & Technologies
Pharmaceuticals
© 2017. All Rights Reserved. Powered by Inteum